ABBVIE AND XILIO THERAPEUTICS ANNOUNCE COLLABORATION AND OPTION AGREEMENT TO DEVELOP NOVEL TUMOR-ACTIVATED IMMUNOTHERAPIES
Source text: ID:nGNX9jY2Q7
Further company coverage: ABBV.N
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.